DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.
about
Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapistsAndrogen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cellsRole of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase.Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction.Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells.Targeting mitotic pathways for endocrine-related cancer therapeutics.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies.Structural and functional association of androgen receptor with telomeres in prostate cancer cells.Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth.Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replaGrowth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.
P2860
Q26773738-D43BE7B0-79BD-4DC6-BE10-1169F01E7ED0Q30415210-29143A2E-FE23-4A79-BF47-0756B65AB8C7Q34599285-CD376029-73AE-4656-BB12-749393784BDCQ36020949-DEF006B0-E89A-47F7-9DB3-AFC7DEA97215Q36283346-F66D77D8-4315-46F7-A5A1-29A9ECD0672EQ37456966-82DEAD63-30C3-4AF9-B682-7E735AA99B3DQ37697163-39C4AC8F-E465-4811-8CEC-E6C0691D4643Q37709925-9F32E732-4022-4DF1-8A8D-149FCFAD20D9Q38433570-ED2A305A-1243-49FC-84AD-0B6724F51B94Q38671036-E8CD3D68-FD29-4201-8AEA-2E3F04DEFC41Q38765489-7FD06757-9043-4B3E-B479-980DB7CE7A2EQ38766081-01FAFDF4-15C9-4549-9C08-44DC3EFC79A1Q38922304-3C266F30-D172-4F27-8969-CB2A1E6C31A3Q38957279-D9172614-CAFE-4E46-AB60-157727A7E0B1Q39201974-ABECF0AD-DB79-4947-BB6C-286E703B3BF1Q39384179-522ABA3F-F1D1-429B-8A92-FE1039A5A1CDQ39813195-D8CA838F-1ABD-4655-9855-D3FDB05F7C5EQ42363301-0BA0B0DD-7149-43B9-BD0C-C8A875E81DF7Q42718194-618D004E-E953-46AE-A394-014442C0B908Q45058251-E0E1E276-F77B-4BAC-BEBE-0C3D80461983Q49631417-74014107-5B22-4D87-AF1A-CF2FF7E87A5FQ51606183-69305D0F-1051-432C-8BA4-D9C813EC9451Q52758659-722C1DEA-D9CB-4E2F-83FD-38D0FA2B69C4
P2860
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
DNA licensing as a novel andro ...... ic target for prostate cancer.
@en
DNA licensing as a novel andro ...... ic target for prostate cancer.
@nl
type
label
DNA licensing as a novel andro ...... ic target for prostate cancer.
@en
DNA licensing as a novel andro ...... ic target for prostate cancer.
@nl
prefLabel
DNA licensing as a novel andro ...... ic target for prostate cancer.
@en
DNA licensing as a novel andro ...... ic target for prostate cancer.
@nl
P2860
P356
P1476
DNA licensing as a novel andro ...... tic target for prostate cancer
@en
P2093
Jason M D'Antonio
John T Isaacs
P2860
P304
P356
10.1677/ERC-08-0205
P577
2009-02-24T00:00:00Z